R&D channel feed – Endpoints News

R&D channel feed

'Our legacy matters': Merck maps out Keytruda kingdom while spotlighting advances in vaccines, hospital care

6 years ago

In starved antibiotic field, Melinta soars as FDA grants speedy drug review

6 years ago

Sanofi's John Reed continues to reorganize R&D, cutting 466 jobs while boosting cancer, gene therapy research

6 years ago

Investor day prep at Merck includes a new strategy to pick up the pace on M&A — report

6 years ago

Study: Just half of postmarketing commitment trials are published

6 years ago

Right back at you, Pfizer: BeiGene and a Pfizer spinout launch a newco to develop a MEK/BRAF inhibitor that could rival $11.4B combo

6 years ago

Sanofi aligns itself with Google to streamline drug development

6 years ago

Roche fields first approval for Rozlytrek in the run-up to a showdown with Bayer, Pfizer

6 years ago

The top 10 blockbuster drugs in the late-stage pipeline — Evaluate adds 6 new therapies to heavy-hitter list

6 years ago

AstraZeneca spinout Viela Bio pockets $75M on its way to BLA for autoimmune drug

6 years ago

Investors fret as VBI's hep B vaccine fails key secondary PhIII study goal

6 years ago

Fueled by early success, Enanta paves way for mid-stage RSV study in adult patients later this year

6 years ago

Newsmakers at #EHA19: Regeneron, ArQule track progress on response rates

6 years ago

BeiGene touts 'encouraging' response rates as the Chinese biotech mounts challenge to BTK, PD-1 leaders

6 years ago

Global Blood Therapeutics poised to submit application for accelerated approval, with new pivotal data on its sickle cell disease drug

6 years ago

Bluebird shares sink as analysts puzzle out $1.8M sticker shock and an unexpected delay

6 years ago

FDA warns of one death linked to fecal transplants

6 years ago

Savara shares are crushed as PhIII trial flunks primary, key secondaries — but they can’t stop believing

6 years ago

As another antibiotics biotech sinks into a crisis, warnings of a sector ‘collapse’

6 years ago

Synlogic, Ginkgo expand microbial discovery pact, throwing $80M investment into the mix

6 years ago

Searching for the next blockbuster to follow Darzalex, J&J finds a $150M anti-CD38 drug from partner Genmab

6 years ago

NASH contender CymaBay runs into trouble as mid-stage data disappoint

6 years ago

'We kept at it': Jeffrey Bluestone plots late-stage comeback after teplizumab shown to delay type 1 diabetes

6 years ago

Aptinyx's lead drug makes cut in small fibromyalgia trial, setting the stage for larger chronic pain study

6 years ago

First page Previous page 241 242 243244245 246 247 Next page Last page